CA2286081A1 - Gastric-retained pharmaceutical composition - Google Patents

Gastric-retained pharmaceutical composition Download PDF

Info

Publication number
CA2286081A1
CA2286081A1 CA002286081A CA2286081A CA2286081A1 CA 2286081 A1 CA2286081 A1 CA 2286081A1 CA 002286081 A CA002286081 A CA 002286081A CA 2286081 A CA2286081 A CA 2286081A CA 2286081 A1 CA2286081 A1 CA 2286081A1
Authority
CA
Canada
Prior art keywords
carbon dioxide
composition according
benzamide
salts
dioxide generator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286081A
Other languages
English (en)
French (fr)
Inventor
Jerôme Besse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286081A1 publication Critical patent/CA2286081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002286081A 1997-04-18 1998-04-15 Gastric-retained pharmaceutical composition Abandoned CA2286081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR97/04803 1997-04-18
FR9704803A FR2762213B1 (fr) 1997-04-18 1997-04-18 Composition pharmaceutique a retention gastrique
PCT/FR1998/000755 WO1998047506A1 (fr) 1997-04-18 1998-04-15 Composition pharmaceutique a residence gastrique

Publications (1)

Publication Number Publication Date
CA2286081A1 true CA2286081A1 (en) 1998-10-29

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286081A Abandoned CA2286081A1 (en) 1997-04-18 1998-04-15 Gastric-retained pharmaceutical composition

Country Status (19)

Country Link
EP (1) EP0983065A1 (ko)
JP (1) JP2001523241A (ko)
KR (1) KR20010006353A (ko)
CN (1) CN1252720A (ko)
AR (1) AR015586A1 (ko)
AU (1) AU737634B2 (ko)
CA (1) CA2286081A1 (ko)
FR (1) FR2762213B1 (ko)
HU (1) HUP0002455A3 (ko)
IL (1) IL131995A0 (ko)
JO (1) JO2017B1 (ko)
MA (1) MA26482A1 (ko)
NO (1) NO995039L (ko)
NZ (1) NZ500288A (ko)
PE (1) PE68199A1 (ko)
PL (1) PL336273A1 (ko)
TN (1) TNSN98049A1 (ko)
WO (1) WO1998047506A1 (ko)
ZA (1) ZA983258B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
WO2009157711A2 (ko) * 2008-06-24 2009-12-30 Park Eun-Seok 위장체류형 다공성 정제 및 그의 제조 방법
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
EP2719376B1 (en) 2012-10-12 2015-03-04 Omya International AG Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
FR2554718B1 (fr) * 1983-11-14 1986-04-04 Ethypharm Sa Nouvelles formes galeniques du sulpiride utilisables par voie orale
FR2556964A1 (fr) * 1983-12-23 1985-06-28 Ile De France Nouvelles formes galeniques du sulpiride utilisables par voie orale
JPS62178518A (ja) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk 新規持続性スルピリド錠剤
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials

Also Published As

Publication number Publication date
EP0983065A1 (fr) 2000-03-08
AU737634B2 (en) 2001-08-23
WO1998047506A1 (fr) 1998-10-29
FR2762213B1 (fr) 1999-05-14
JP2001523241A (ja) 2001-11-20
ZA983258B (en) 1998-10-19
KR20010006353A (ko) 2001-01-26
HUP0002455A2 (hu) 2000-12-28
NZ500288A (en) 2001-03-30
JO2017B1 (en) 1999-05-15
NO995039D0 (no) 1999-10-15
TNSN98049A1 (fr) 2005-03-15
AR015586A1 (es) 2001-05-16
AU7341698A (en) 1998-11-13
MA26482A1 (fr) 2004-12-20
CN1252720A (zh) 2000-05-10
PL336273A1 (en) 2000-06-19
IL131995A0 (en) 2001-03-19
FR2762213A1 (fr) 1998-10-23
HUP0002455A3 (en) 2001-01-29
NO995039L (no) 1999-12-17
PE68199A1 (es) 1999-07-15

Similar Documents

Publication Publication Date Title
US20220133778A1 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20120142737A1 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
CA2609627C (en) Pharmaceutical formulations useful for inhibiting acid secretion
AU1451201A (en) Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
US20120071537A1 (en) New Oral Formulation
JP2002529407A (ja) L−dopaエチルエステル含有分散性組成物
AU737634B2 (en) Pharmaceutical composition for gastric residence
JP2003519656A (ja) 新規な置換ベンズイミダゾール投与形態およびそれらの使用方法
FI117373B (fi) Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
PT96506B (pt) Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano
US5213806A (en) Pharmaceutical composition comprising calcium polycarbophil
JP3110794B2 (ja) 1,4−ジヒドロピリジン誘導体を含有する製剤
US20010046473A1 (en) Gastric-retained pharmaceutical composition and method for its use
AU6848700A (en) Floating pharmaceutical composition comprising an active phase and a non-active phase
JP5721093B2 (ja) 崩壊錠
WO2005051350A2 (en) Water dispersible tablet
JP2005112825A (ja) 胃内浮遊性固形製剤
KR880002139B1 (ko) 경구 투여용 정제의 제조방법
EP1353624B1 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
KR20040091135A (ko) 염산 필지카이니드 함유 정제(건식)
KR101641319B1 (ko) 안정성이 개선된 에카베트와 라니티딘의 복합 제제
CZ364099A3 (cs) Farmaceutický prostředek vhodný pro zadržení v žaludku
AU2011265561B2 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005331781C1 (en) Pharmaceutical formulations useful for inhibiting acid secretion
KR20050002856A (ko) 염산 필지카이니드 함유 정제(습식)

Legal Events

Date Code Title Description
FZDE Discontinued